<?xml version='1.0' encoding='utf-8'?>
<document id="21550074"><sentence text="Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients."><entity charOffset="0-9" id="DDI-PubMed.21550074.s1.e0" text="Ritonavir" /><entity charOffset="32-41" id="DDI-PubMed.21550074.s1.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.21550074.s1.e0" e2="DDI-PubMed.21550074.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21550074.s1.e0" e2="DDI-PubMed.21550074.s1.e1" /></sentence><sentence text="Prasugrel is an antiplatelet prodrug used in patients with acute coronary syndrome"><entity charOffset="0-9" id="DDI-PubMed.21550074.s2.e0" text="Prasugrel" /></sentence><sentence text=" Prasugrel is mainly bioactivated by cytochromes P450 3A4/5 and CYP2B6"><entity charOffset="1-10" id="DDI-PubMed.21550074.s3.e0" text="Prasugrel" /></sentence><sentence text=" HIV patients are at risk of cardiovascular disease, and the protease inhibitor ritonavir is a potent inhibitor of these 2 CYPs"><entity charOffset="80-89" id="DDI-PubMed.21550074.s4.e0" text="ritonavir" /></sentence><sentence text=" The aim of this in vitro study was to determine the impact of ritonavir in prasugrel metabolism"><entity charOffset="63-72" id="DDI-PubMed.21550074.s5.e0" text="ritonavir" /><entity charOffset="76-85" id="DDI-PubMed.21550074.s5.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.21550074.s5.e0" e2="DDI-PubMed.21550074.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21550074.s5.e0" e2="DDI-PubMed.21550074.s5.e1" /></sentence><sentence text=" Human liver microsomes (HLMs) and recombinant microsomes were used to identify the enzymes responsible for the bioactivation of prasugrel"><entity charOffset="129-138" id="DDI-PubMed.21550074.s6.e0" text="prasugrel" /></sentence><sentence text=" Prasugrel concentrations of 5 to 200 μM were used for Km determination"><entity charOffset="1-10" id="DDI-PubMed.21550074.s7.e0" text="Prasugrel" /></sentence><sentence text=" Inhibition by ritonavir was characterized using HLMs at concentrations of 0"><entity charOffset="15-24" id="DDI-PubMed.21550074.s8.e0" text="ritonavir" /></sentence><sentence text="1 to 30 μM" /><sentence text=" Prasugrel active metabolite determination was performed with a validated liquid chromatography-mass spectrometry method"><entity charOffset="1-10" id="DDI-PubMed.21550074.s10.e0" text="Prasugrel" /></sentence><sentence text=" Using recombinant microsomes, prasugrel biotransformation was mainly performed by CYP2B6, CYP2D6, CYP2C19, CYP3A4, and CYP3A5"><entity charOffset="31-40" id="DDI-PubMed.21550074.s11.e0" text="prasugrel" /></sentence><sentence text=" With specific inhibitors of CYP3A, CYP2B6, CYP2D6, CYP2C9, and CYP2C19, active metabolite production was decreased by 38% ± 15% with 4-(4-chlorobenzyl)pyridine (CYP2B6 inhibitor) and by 45 ± 16% with ketoconazole (CYP3A inhibitor)"><entity charOffset="134-160" id="DDI-PubMed.21550074.s12.e0" text="4-(4-chlorobenzyl)pyridine" /><entity charOffset="201-213" id="DDI-PubMed.21550074.s12.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21550074.s12.e0" e2="DDI-PubMed.21550074.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21550074.s12.e0" e2="DDI-PubMed.21550074.s12.e1" /></sentence><sentence text=" The Km value for prasugrel metabolism in HLMs was determined to be 92"><entity charOffset="18-27" id="DDI-PubMed.21550074.s13.e0" text="prasugrel" /></sentence><sentence text="5 μM" /><sentence text=" Ritonavir at 0"><entity charOffset="1-10" id="DDI-PubMed.21550074.s15.e0" text="Ritonavir" /></sentence><sentence text="1 to 30 μM was shown to be a potent dose-dependent inhibitor of prasugrel"><entity charOffset="64-73" id="DDI-PubMed.21550074.s16.e0" text="prasugrel" /></sentence><sentence text=" In this in-vitro study, we found a potent inhibition of prasugrel bioactivation by ritonavir compared to the specific inhibitors of CYP3A and CYP2B6 due to the simultaneous inhibition of CYP2B6 and CYP3A by ritonavir"><entity charOffset="57-66" id="DDI-PubMed.21550074.s17.e0" text="prasugrel" /><entity charOffset="84-93" id="DDI-PubMed.21550074.s17.e1" text="ritonavir" /><entity charOffset="208-217" id="DDI-PubMed.21550074.s17.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.21550074.s17.e0" e2="DDI-PubMed.21550074.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21550074.s17.e0" e2="DDI-PubMed.21550074.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21550074.s17.e0" e2="DDI-PubMed.21550074.s17.e2" /><pair ddi="false" e1="DDI-PubMed.21550074.s17.e1" e2="DDI-PubMed.21550074.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21550074.s17.e1" e2="DDI-PubMed.21550074.s17.e2" /></sentence><sentence text=" This finding suggests a potential significant drug-drug interaction between these two drugs" /><sentence text="" /></document>